The US MPS VI drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is a progressive condition that causes many tissues and organs to enlarge and become inflamed or scarred. Skeletal abnormalities are also common in this condition. Apart from the recent regulatory approvals, there has been increasing activity in the R&D for the Morquio syndrome treatment as evidenced by the greater inclusion of the disorder in the clinical pipelines of the major market players. This combined with the greater awareness of the disease is also driving the growth in Morquio syndrome treatment market.
The growth in the number of products in the preliminary and advanced stages of R&D along with the focus on treatment of rare diseases is anticipated to drive the growth in the Morquio syndrome treatment market at a considerably fast rate. With the recent approval of the elosulfase alpha (VIMIZIM), the market is expected to be boosted several products currently in the pipeline of various companies can be anticipated to undergo regulatory approvals for the marketing, if they have favourable clinical trials results. Market players are more focused on adoption of inorganic growth strategies such as collaborations and partnerships to strengthen their position in the US mucopolysaccharidosis (MPS) treatment market. Adoption of inorganic growth strategies by key players is expected to drive the market growth over the forecast period.